drugset / Trial / NCT00405405
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
Phase 1
Completed
13 enrolled
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
To determine a safe and effective doses of two biologic drugs, erlotinib and bevacizumab when used with chemotherapy and radiation therapy in advanced head and neck cancer
Timeline
- Start
- 2006-12
- Primary completion
- 2010-06
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Erlotinib | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Docetaxel | Small molecule | — | — |